Gynecologic Oncology Reports (Nov 2020)
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
- Johnathan Oh,
- Minal Barve,
- Neil Senzer,
- Phylicia Aaron,
- Luisa Manning,
- Gladice Wallraven,
- Ernest Bognar,
- Laura Stanbery,
- Staci Horvath,
- Meghan Manley,
- John Nemunaitis,
- Adam Walter,
- Rodney P. Rocconi
Affiliations
- Johnathan Oh
- Texas Oncology, P.A., Dallas, TX, United States
- Minal Barve
- Texas Oncology, P.A., Dallas, TX, United States; Mary Crowley Cancer Research Centers, Dallas, TX, United States
- Neil Senzer
- Gradalis, Inc., Carrolton, TX, United States
- Phylicia Aaron
- Gradalis, Inc., Carrolton, TX, United States
- Luisa Manning
- Gradalis, Inc., Carrolton, TX, United States
- Gladice Wallraven
- Gradalis, Inc., Carrolton, TX, United States
- Ernest Bognar
- Gradalis, Inc., Carrolton, TX, United States
- Laura Stanbery
- Gradalis, Inc., Carrolton, TX, United States
- Staci Horvath
- Gradalis, Inc., Carrolton, TX, United States
- Meghan Manley
- Gradalis, Inc., Carrolton, TX, United States
- John Nemunaitis
- Corresponding author at: 2545 Golden Bear Dr., Suite 110, Carrollton, TX 75006, United States.; Gradalis, Inc., Carrolton, TX, United States
- Adam Walter
- ProMedica, Toledo, OH, United States
- Rodney P. Rocconi
- University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States
- Journal volume & issue
-
Vol. 34
p. 100648
